Deferasirox: Oral Iron Chelator Targeting Tumor Iron Metabolism

Executive Summary: Deferasirox is an orally active iron chelator approved for iron-overload disorders and increasingly studied in cancer research. Its mechanism involves binding free iron and disrupting iron uptake from transferrin, thereby inhibiting tumor cell proliferation and growth [APExBIO]. Preclinical studies demonstrate increased apoptosis via caspase-3 activation in cancer models. Deferasirox is insoluble in water, soluble in DMSO and ethanol, and should be stored at -20°C [APExBIO]. Recent literature highlights its value in overcoming ferroptosis resistance by targeting iron metabolism (Wang et al., 2024).

Biological Rationale

Iron is essential for DNA synthesis, cellular respiration, and proliferation. Cancer cells exhibit elevated iron requirements, often exploiting transferrin-mediated uptake to support rapid growth (Wang et al., 2024). Iron overload leads to increased oxidative stress and lipid peroxidation, processes exploited by tumors but also representing vulnerabilities. Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation, distinct from apoptosis. Resistance to ferroptosis underlies therapeutic failure in certain cancers, including hepatocellular carcinoma (HCC) (Wang et al., 2024). Targeting iron metabolism—by chelation—can disrupt both tumor proliferation and ferroptosis resistance, positioning iron chelators such as Deferasirox at the crossroads of oncology and metabolic therapy [see related].

Mechanism of Action of Deferasirox

Deferasirox (C₂₁H₁₅N₃O₄, MW 373.37 g/mol) acts as a tridentate iron chelator. It binds ferric (Fe³⁺) ions to form soluble complexes, thereby reducing the labile iron pool and facilitating excretion [APExBIO]. In cancer biology, Deferasirox impedes iron uptake from human transferrin, limiting the supply needed for tumor cell division. Mechanistic studies reveal upregulation of cleaved caspase-3 and poly(ADP-ribose) polymerase 1 (PARP1), markers of apoptosis, and induction of the cyclin-dependent kinase inhibitor p21^CIP1/WAF1. It also increases expression of the metastasis suppressor N-myc downstream-regulated gene 1 (NDRG1) and decreases cyclin D1, contributing to anti-proliferative and anti-metastatic activity. By reducing iron availability, Deferasirox can sensitize cells to ferroptosis—a feature exploited in translational cancer models (Wang et al., 2024).

Evidence & Benchmarks

• Deferasirox inhibits proliferation of DMS-53 lung carcinoma and SK-N-MC neuroepithelioma cells in vitro [APExBIO].
• In vivo, Deferasirox reduces tumor volume in nude mice bearing DMS-53 xenografts; administration: oral, dosage not specified, study duration ≥14 days [APExBIO].
• Deferasirox increases cleaved caspase-3 and cleaved PARP1, indicating apoptosis induction in tumor cells [APExBIO].
• Iron chelation therapy with Deferasirox modulates the METTL16-SENP3-LTF axis, overcoming ferroptosis resistance and suppressing hepatocellular carcinoma progression (Wang et al., 2024).
• Deferasirox is insoluble in water, soluble in DMSO (≥37.28 mg/mL), and ethanol (≥2.94 mg/mL, ultrasonic assistance), requiring storage at -20°C [APExBIO].
• Related research on translational application and mechanistic rationale for Deferasirox in cancer is discussed in this article, which this review extends by integrating recent insights on the METTL16-SENP3-LTF axis.

Applications, Limits & Misconceptions

Deferasirox is FDA-approved for iron overload in conditions such as thalassemia and myelodysplastic syndromes. Its emerging application in oncology leverages its ability to disrupt tumor iron metabolism and induce cell death. Preclinical models demonstrate efficacy in lung carcinoma, neuroepithelioma, and HCC, with ongoing studies expanding to other malignancies. Notably, Deferasirox can modulate cellular sensitivity to ferroptosis, offering a strategy for tumors resistant to apoptosis or conventional therapies. For an expanded mechanistic and translational perspective, see the discussion in 'Deferasirox in Cancer Therapy: Targeting Iron Metabolism', to which the present article adds recent evidence on ferroptosis axis modulation.

Common Pitfalls or Misconceptions

• Deferasirox is not effective in acute iron poisoning: It is indicated for chronic iron overload, not for emergency chelation [APExBIO].
• Water insolubility limits certain assay formats: Deferasirox is insoluble in water and must be dissolved in DMSO or ethanol for experimental use.
• Long-term solution storage is not recommended: Deferasirox solutions degrade over time and should be freshly prepared.
• Not universally cytotoxic: Efficacy varies by cell type, iron status, and tumor genotype; not all cancers are sensitive to iron chelation-induced apoptosis.
• Does not directly induce ferroptosis: Instead, it sensitizes cells by lowering iron, and its effect may be context-dependent on ferroptosis pathways.

Workflow Integration & Parameters

For experimental protocols, Deferasirox is typically dissolved in DMSO (≥37.28 mg/mL) or ethanol (≥2.94 mg/mL with sonication). Recommended storage is at -20°C, and solutions should be prepared fresh for each use. In vitro cell proliferation and apoptosis assays use concentrations ranging from 1–100 µM, with vehicle controls. In vivo, administration is by oral gavage, with dosage and schedule tailored to the animal model. For detailed workflow integration and advanced strategies using Deferasirox to modulate iron metabolism and ferroptosis, refer to 'Deferasirox: Redefining Iron Chelation Therapy in Tumor Fields', which this article updates by including recent clinical and mechanistic developments.

Conclusion & Outlook

Deferasirox is established as a leading oral iron chelator with proven efficacy in iron chelation therapy for iron overload. Its anti-tumor potential is increasingly supported by evidence demonstrating inhibition of tumor growth, apoptosis induction, and modulation of ferroptosis resistance pathways. Ongoing research is defining the boundaries and optimal applications of Deferasirox in translational oncology, with future work needed to clarify its role in combination therapies and resistance mechanisms. For more details or to obtain the A8639 kit, refer to the APExBIO product page.